Same Specs, Different Risk
This segment of the Outsourced Pharma Live event, “Your CDMO Quality Oversight Is Not Working,” challenges the assumption that switching raw material suppliers carries little risk when specifications remain unchanged. Andrea and Greg discuss supplier qualification, the material’s role in the manufacturing process, and the evidence sponsors should examine before accepting a change, including when document comparisons need support from small-scale experiments. Greg also shares how seemingly equivalent substitutions have led to failed batches and lengthy investigations. Featuring Andrea Goddard, CTO, CatalYm GmbH, and Greg Whitehead, EVP/CTO, Editas Medicine.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.